The use of triptans for pediatric migraines

Pediatric Drugs

Volumn 12, Issue 6, 2010, Pages 379-389

  Eiland, Lea S ^a   Hunt, Melissa O ^b  

^a AUBURN UNIVERSITY   (United States)

^b HUNTSVILLE HOSPITAL   (United States)

Author keywords

Adolescents; Almotriptan, therapeutic use; Children; Eletriptan, therapeutic use; Frovatriptan, therapeutic use; Migraine, treatment; Naratriptan, therapeutic use; Rizatriptan, therapeutic use; Serotonin 1B receptor agonists, therapeutic use; Serotonin 1D receptor agonists, therapeutic use; Sumatriptan, therapeutic use; Zolmitriptan, therapeutic use.

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; IBUPROFEN; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ABDOMINAL PAIN; ASTHENIA; BURNING SENSATION; CHEST TIGHTNESS; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INJECTION SITE REACTION; MIGRAINE; MUSCLE STIFFNESS; NAUSEA; NOSE CONGESTION; NOSE DISEASE; OPTIMAL DRUG DOSE; PAIN; PARESTHESIA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SOMNOLENCE; TASTE DISORDER; TREATMENT RESPONSE; VOMITING; XEROSTOMIA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRYPTAMINES;

EID: 78049371010     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11532860-000000000-00000     Document Type: Review

References (52)

1. Lewis D, Ashwal S, Hershey A, et al., on behalf of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004; 63: 2215-24
2. Fenichel GM. Headache. In: Fenichel GM. Clinical pediatric neurology. 5th ed. Philadelphia (PA): Elsevier Saunders, 2005: 77-89
3. Kabbouche MA, Linder SL. Acute treatment of pediatric headache in the emergency department and inpatient settings. Pediatr Ann 2005; 34: 466-71
4. Hershey AD, Winner PK. Pediatric migraine: recognition and treatment. J Am Osteopath Assoc 2005; 105: 2-8S
5. International Headache Society. International classification of headache disorders. 2nd ed. Cephalalgia 2004; 24: S23-136
6. Winner P, Rothner AD, Putnam DG, et al. Demographic and migraine characteristics ofadolescents with migraine: Glaxo Wellcome clinical trials' data-base. Headache 2003; 43: 451-7
7. Lewis DW. Pediatric migraine. Neurol Clin 2009; 27: 481-501
8. Evers S. EFNS guideline on the drug treatment ofmigraine-revised report of an EFNS task force. Eur J Neurol2009; 16: 968-81
9. European Medicines Agency. Assessment of the paediatric needs migraine [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/paediatrics/ 22451506en.pdf[Accessed 2009 Nov 17]
10. Taketomo CK, Hodding JH, Kraus DM. Pediatric dosing handbook. 14th ed. Hudson: Lexi-Comp, 2007-2008 Drugs for migraines. Treat Guidel Med Lett 2008; 6: 17-22
11. Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebocontrolled study of sumatriptan nasal spray in the treatment ofacute migraine in adolescents. Pediatrics 2000; 106: 989-97
12. Winner P, Rothner AD, Wooten JD, et al. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind placebo-controlled acute study. Headache 2006; 46: 212-22
13. Ahonen K, Hamalainen ML, Rantala H, et al. Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology 2004; 62: 883-7
14. Ueberall MA, Wenzel D. Intranasal sumatriptan for the acute treatment of migraine in children. Neurology 1999; 52: 1507-10
15. Hershey AD, Powers SW, LeCates S, et al. Effectiveness ofnasal sumatriptan in 5-to 12-year-old children. Headache 2001; 41: 693-7
16. Pakalnis A, Kring D, Paolicchi J. Parental satisfaction with sumatriptan nasal spray in childhood migraine. J Child Neurol2003; 18: 772-5
17. Natarajan S, Jabbour JT, Webster CJ, et al. Long term tolerability of sumatriptan nasal spray in adolescent patients with migraine. Headache 2004; 44: 969-77
18. Rothner AD, Winner P, Nett R, et al. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. Clin Ther 2000; 22: 1533-46
19. Blumenthal HJ. Butterscotch masks the bitter taste of sumatriptan nasal spray [letter]. Headache 2001; 41: 210
20. MacDonald JT. Treatment ofjuvenile migraine with subcutaneous sumatriptan. Headache 1994; 34: 581-2
21. Linder SL. Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in a pediatric neurology office practice. Headache 1996; 36: 419-22
22. Imitrex (sumatriptan): product information. Research Triangle Park (NC): GlaxoSmithKline, 2007 Oct
23. Winner P, Prensky A, Linder S, et al. Adolescent migraine: efficacy and safety of sumatriptan tablets [abstract]. J Neurol Sci 1997; 150: S172
24. Korsgaard AG. The tolerability, safety and efficacy oforal sumatriptan 50 mg and 100mg for the acute treatment ofmigraine in adolescents [abstract]. Cephalalgia 1995; 15: S99
25. Hamalainen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differentlyfromadults? Neurology 1997; 48:1100-3
26. Rothner D, Asgharnejad M. Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials [abstract]. Eur J Neurol 1999; 6: 106
27. Erbilen E, Ozhan H, Akdemir R, et al. A case ofmyocardial infarction with sumatriptan use. Pediatr Cardiol 2005; 26: 464-6
28. Hoffman RJ, Ginsburg BY, Nelson LS, et al. Acute coronary syndrome following subcutaneous sumatriptan administration in a child. Clin Toxicol 2005; 43: 634-5
29. Christensen ML, Mottern RK, Jabbour JT, et al. Pharmacokinetics ofsumatriptan nasal spray in children. J Clin Pharmacol 2004; 44: 359-67
30. Christensen ML, Mottern RK, Jabbour JT, et al. Pharmacokinetics ofsumatriptan nasal spray in adolescents. J Clin Pharmacol 2003; 43: 721-6
31. Ahonen K, Hamalainen ML, Eerola M, et al. A randomized trial of rizatriptan in migraine attacks in children. Neurology 2006 Aug; 67: E1135-40
32. Winner P, Lewis D, Visser WH, et al., on behalf of the Rizatriptan Adolescent Study Group. Rizatriptan 5mg for the acute treatment ofmigraine in ado-lescents: a randomized, double-blind, placebo-controlled study. Headache 2002; 42: 49-55
33. Visser WH, Winner P, Strohmaier K, et al., on behalf of the Rizatriptan Protocol 059 and 061 Study Groups. Rizatriptan 5mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache 2004; 44: 891-9
34. Smith TR. Efficacy and tolerability of the marketed doses of rizatriptan in children and adolescents: a retrospective review [abstract]. Cephalalgia 2001; 21: 461-2
35. Winner P, Gladstein J, Hershey AD. Effectiveness and tolerability of rizatriptan in adolescents with migraine [abstract]. Neurology 2002; 58: A289-90
36. Winner P, Sadowski C, Pate D. Pharmacokinetics of rizatriptan in adolescent migraineurs [abstract]. Headache 1998; 38: 411
37. Linder SL, Dowson AJ. Zolmitriptan provides effective migraine relief in adolescents. Int J Clin Pract 2000; 54: 466-9
38. Rothner AD, Wasiewski W, Winner P, et al. Zolmitriptan oral tablet in migraine treatment: highplacebo responses in adolescents. Headache 2006; 46: 101-9
39. Evers S, Rahmann A, Kraemer C, et al. Treatment of childhood migraine attacks withoralzolmitriptan andibuprofen. Neurology 2006 Jun; 67: E497-9
40. Wasiewski W, Winner PK. Zolmitriptan is well tolerated in adolescents [abstract]. Ann Neurol 1999; 46: 541
41. Dixon R, Engleman K, Kemp J, et al. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adoles-cents and adults. J Child Adolesc Psychopharmacol 1999; 9: 35-42
42. Lewis DW, Winner P, Hershey AD, et al., onbehalf of the Adolescent Migraine Steering Committee. Efficacy of zolmitriptan nasal spray in adolescent mi-graine. Pediatrics 2007; 120: 390-6
43. Rothner A. Efficacy and safety of naratriptan tablets in adolescent migraine [abstract]. J Neurol Sci 1997; 150: S106
44. Sallucci C. Naratriptan vs. ibuprofen in acute migraine treatment in children [abstract]. Cephalalagia 2000; 20: 287
45. Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine. J Clin Pharmacol 2001; 41: 170-5
46. Charles JA. Almotriptan in the acute treatment ofmigraine in patients 11-17 years old: an open-label pilot study ofefficacy and safety. J Headache Pain 2006 Apr; 7: E95-7
47. Linder SL, Mathew NT, Cady RK, et al. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache 2008; 48: 1326-36
48. Baldwin JR, Fleishaker JC, Azie NE. A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy ado-lescents and adults. Cephalalgia 2004; 24: 288-92
49. Winner P, Linder SL, Lipton RB, et al. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache 2007; 47: 511-8
50. Elkind AH, Wade A, Ishkanian G. Pharmacokinetics of frovatriptan in adolescent migraineurs. J Clin Pharmacol 2004; 44: 1158-65
51. Lewis DW, Winner P, Wasiewski W. The placebo responder rate in children and adolescents. Headache 2005; 45: 232-9
52. US Food and Drug Administration. Drugs@FDA.gov: FDA approved drug products. US FDA database [online]. Available from URL: http://www. accessdata.fda.gov/scripts/cder/drugsatfda/[Accessed 2009 Aug 11]